New and Updated - Books

New & Updated

Here is a list of recently added titles to Bookshelf and updated books and releases

Recent Releases

Use of Meta-Analyses in Nutrition Research and Policy: Proceedings of a Workshop Series.

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Food and Nutrition Board; Flaxman M, Maitin-Shepard M, editors.

Washington (DC): National Academies Press (US); 2024 Apr 23.

Added 05-09-2024

Fostamatinib (Tavalisse): CADTH Reimbursement Review: Therapeutic area: Chronic immune thrombocytopenia [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Improving Access to Primary Care: Environmental Scan [Internet].

Darvesh N, McGill SC; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Accelerating and Deepening Approaches to FAIR Data Sharing: Proceedings of a Workshop—in Brief.

National Academies of Sciences, Engineering, and Medicine; Policy and Global Affairs; Board on Research Data and Information; Whitacre P, editor.

Washington (DC): National Academies Press (US); 2024 May 2.

Added 05-09-2024

Selpercatinib (Retevmo): CADTH Reimbursement Recommendation: Indication: Adult patients with rearranged during transfection (RET) fusion-positive differentiated thyroid carcinoma with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Selpercatinib (Retevmo): CADTH Reimbursement Review: Therapeutic area: RET fusion–positive non–small cell lung cancer [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Guidance Statement [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Normal Immunoglobulin (Human) 10% and Recombinant Human Hyaluronidase (HyQvia): CADTH Reimbursement Recommendation: Indication: As replacement therapy for primary humoral immunodeficiency and secondary humoral immunodeficiency in adult patients [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Nivolumab (Opdivo): CADTH Reimbursement Review: Therapeutic area: Gastric, gastroesophageal junction, or esophageal adenocarcinoma [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Guanfacine for Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disorder, and/or Oppositional Defiance Disorder: Rapid Review [Internet].

Jahagirdar D, Mahood Q; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

View More Recent Releases

Avalglucosidase Alfa (Nexviazyme): CADTH Reimbursement Recommendation: Indication: For the long-term treatment of patients with late-onset Pompe disease (acid alpha-glucosidase deficiency) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Multiple Prosthetic Sockets for Lower Limb Amputations: Rapid Review [Internet].

Young C, Mahood Q; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Intermittently Scanned and Real-Time Continuous Glucose Monitoring for People With Diabetes: Rapid Review [Internet].

Farrell K, Loshak H; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Tafamidis Meglumine (Vyndaqel): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Lenvatinib (Lenvima) in Combination With Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: Treatment of adult patients with advanced (not amenable to curative surgery or radiation) or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic RCC [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Lisocabtagene Maraleucel (Breyanzi): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma: Rapid Review [Internet].

Cowling T, Neilson H, Nayakarathna R, et al.; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Cenegermin (Oxervate): CADTH Reimbursement Recommendation: Indication: For the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta): CADTH Reimbursement Recommendation: Indication: Treatment of cystic fibrosis in patients aged 6 years and older who have at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator gene [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Amifampridine Phosphate (Firdapse): CADTH Reimbursement Recommendation: Indication: For the treatment of Lambert-Eaton myasthenic syndrome in adults [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Diacetylmorphine for Adults With Opioid Dependence: Rapid Review [Internet].

Tran K, MacDougall D; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Evidence review for CVD risk assessment tools: primary prevention: Cardiovascular disease: risk assessment and reduction, including lipid modification: Evidence review A.

London: National Institute for Health and Care Excellence (NICE); 2023 May. (NICE Guideline, No. 238.)

Added 05-09-2024

Trace Amine-Associated Receptor 1 Agonists for Schizophrenia: Emerging Health Technologies [Internet].

Vannabouathong C, Picheca L, Dyrda P; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Platform, Basket, and Umbrella Trial Designs: Issues Around Health Technology Assessment of Novel Therapeutics: Discussion Paper [Internet].

Tarride JE, Cheung M, Hanna TP, et al.; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Platform, Basket, and Umbrella Trial Designs: Stakeholder Perspectives of Novel Therapeutics: Discussion Paper [Internet].

Mittmann N, Chan KKW, Cheung M, et al.; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Added 05-09-2024

Updated

RSS Feed

RSS Feed for New Releases

Recent Activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on